Search

Your search keyword '"Can-Fite BioPharma Ltd."' showing total 954 results
Start Over Descriptor "Can-Fite BioPharma Ltd."
954 results on '"Can-Fite BioPharma Ltd."'

1. Can Fite Biopharma Ltd Investor Webinar - Final

Subjects
Can-Fite BioPharma Ltd., Biological products industry, Stock-exchange, Chief operating officers, Chief financial officers, Pharmaceutical industry, Business
Abstract

Presentation UNIDENTIFIED PARTICIPANT: Craig with RedChip company. Thank you for joining today's event with Can-Fite Biopharma, which trades on the New York Stock Exchange American under the ticker CANS. With [...]

Published
2024

4. Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry
Abstract

ENPNewswire-October 8, 2024--Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29 (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 07102024 - Israel - Can-Fite BioPharma Ltd. (NYSE American: CANF) [...]

Published
2024

5. Can Fite Biopharma Ltd Investor Webinar and Q&A Session - Final

Subjects
Can-Fite BioPharma Ltd., Biological products industry, Pharmaceutical industry, Business
Abstract

Presentation PAUL KUNTZ, IR, REDCHIP COMPANIES INC.: Hello, everyone, and welcome. This is Paul Kuntz with RedChip Companies. I want to thank you all for joining today's event with Can-Fite [...]

Published
2024

6. Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

Subjects
Can-Fite BioPharma Ltd., Antiarthritic agents, Osteoarthritis, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

RAMAT GAN: Can-Fite BioPharma Ltd. today announces that its veterinary partner Vetbiolix exercised its option and signed a development and commercialization agreement with Can-Fite for the development of Piclidenoson for [...]

Published
2024

7. Can-Fite Reports First Half 2024 Financial Results & Progress In Two Pivotal Phase III Clinical Studies

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Clinical trials, Osteoarthritis, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

RAMAT GAN: Can-Fite BioPharma Ltd., announced financial results and clinical updates for H1 2024. Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds - in August, the Company announced [...]

Published
2024

8. Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Antiarthritic agents, Clinical trials, Osteoarthritis, Pharmaceutical industry, Banking, finance and accounting industries, Business
Abstract

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=BqWnKCsjw1DTAzHrHjsdg5BzPM4Sd7UTJIqy-mVxFeEOocEGhCyJnH8iSoYbVcGmT5nhw1NuiLlW6UIfQDh1bhY0ALdN4cw7GwgRrP3TyMI=. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and [...]

Published
2024

9. Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Subjects
United States. Securities and Exchange Commission, Can-Fite BioPharma Ltd., Pharmaceutical industry, Banking, finance and accounting industries, Business
Abstract

RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address [...]

Published
2024

10. Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Orphan drugs, Pancreatic cancer -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: Can-Fite BioPharma Ltd. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs [...]

Published
2024

11. Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Subjects
Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Medical centers, Cancer patients -- Care and treatment, Pharmaceutical industry, Liver cirrhosis -- Care and treatment, General interest, News, opinion and commentary
Abstract

Ramat Gan: Can-Fite BioPharma Ltd. announced that a patient with liver decompensated cirrhosis who was treated with Namodenoson at the Soroka Medical Center in Israel under compassionate use showed an [...]

Published
2024

12. Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry, Liver cirrhosis -- Development and progression -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=1bUt-iKYwWKL86n1zf7xy82V-NjfZFYClfeiWyJqjuH_s3OB33hXSwsa4CJnSTFYGsNcPvZ3cH5vsBwVY9khOahFiVGfnFw3i1l5_VvN43U= Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology [...]

Published
2024

13. Can-Fite BioPharma announces new data from anti-obesity drug Namodenoson

Subjects
Can-Fite BioPharma Ltd., Biological products industry, Obesity -- Drug therapy, Weight reducing preparations, Pharmaceutical industry, Pharmaceuticals and cosmetics industries
Abstract

Can-Fite BioPharma Ltd, an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory [...]

Published
2023

15. Can-Fite enters agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs utilizing AI and ML techniques

Subjects
Can-Fite BioPharma Ltd., Drugs -- Methods, Machine learning -- Methods, Pharmaceutical industry -- Methods, Pharmaceuticals and cosmetics industries
Abstract

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, announced that it entered into an agreement with Collaborations Pharmaceuticals, [...]

Published
2023

18. Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Subjects
Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Cancer -- Care and treatment, Liver cancer -- Research, Pharmaceutical industry -- Research, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: CAN-FITE BIOPHARMA LTD. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs [...]

Published
2024

19. Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Subjects
Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Drug discovery, Cancer -- Care and treatment, Liver cancer, Pharmaceutical industry, Business, Business, international
Abstract

PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today [...]

Published
2024

20. Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Subjects
Can-Fite BioPharma Ltd., Oncology, Experimental, Medical centers, Cancer -- Care and treatment -- Research, Drug approval, Pancreatic cancer -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: CAN-FITE BIOPHARMA LTD. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs [...]

Published
2024

21. Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Subjects
Can-Fite BioPharma Ltd., Oncology, Experimental, Medical centers, Cancer -- Care and treatment -- Research, Drug approval, Pancreatic cancer -- Development and progression -- Drug therapy, Pharmaceutical industry, Business, Business, international
Abstract

Namodenoson showed efficacy in pre-clinical models via a definitive molecular mechanism of action PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a [...]

Published
2024

22. Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Oncology, Experimental, Orphan drugs, Cancer -- Care and treatment -- Research, Liver cancer -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

RAMAT GAN: CAN-FITE BIOPHARMA LTD. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that [...]

Published
2024

23. CAN-FITE UPDATES ON ITS ADVANCED LIVER CANCER PIVOTAL PHASE 3 STUDY

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Pharmaceutical industry
Abstract

ENPNewswire-June 6, 2024--CAN-FITE UPDATES ON ITS ADVANCED LIVER CANCER PIVOTAL PHASE 3 STUDY (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 05062024 - Israel - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: [...]

Published
2024

24. Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Oncology, Experimental, Orphan drugs, Cancer -- Care and treatment -- Research, Liver cancer -- Development and progression -- Drug therapy, Pharmaceutical industry, Business, Business, international
Abstract

Namodenoson granted Orphan Drug and Fast track status from the FDA RAMAT GAN, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary [...]

Published
2024

25. Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Subjects
Can-Fite BioPharma Ltd., Heart diseases -- Drug therapy, Drugs -- Health aspects, Scientists -- Health aspects, Pharmaceutical industry -- Health aspects, Business, Business, international
Abstract

RAMAT-GAN, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported [...]

Published
2024

26. CAN-FITE TO PARTICIPATE IN PARTNERING MEETINGS AT BIO INTERNATIONAL CONVENTION 2024

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry
Abstract

ENPNewswire-May 28, 2024--CAN-FITE TO PARTICIPATE IN PARTNERING MEETINGS AT BIO INTERNATIONAL CONVENTION 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 27052024 - Israel - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: [...]

Published
2024

27. Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry, Business, Business, international
Abstract

RAMAT GAN, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, is pleased [...]

Published
2024

28. Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

RAMAT GAN: Can-Fite BioPharma Ltd. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that [...]

Published
2024

30. Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Liver, Clinical trials, Pharmaceutical industry, Business, Business, international
Abstract

RAMAT GAN, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces [...]

Published
2024

31. LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Pharmaceutical industry
Abstract

ENPNewswire-April 26, 2024--LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 25042024 - PETACH [...]

Published
2024

32. Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Oncology, Experimental, Cancer patients -- Care and treatment, Liver cancer -- Care and treatment, Cancer -- Research, Pharmaceutical industry, Business, Business, international
Abstract

PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today [...]

Published
2024

38. Can-Fite to provide Namodenoson as compassionate use treatment for decompensated liver cirrhosis patients

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Global Banking News-March 13, 2023-Can-Fite to provide Namodenoson as compassionate use treatment for decompensated liver cirrhosis patients (C)2023 ENPublishing - http://www.enpublishing.co.uk Biotechnology company Can-Fite BioPharma Ltd (NYSE American: CANF) (TASE:CFBI), [...]

Published
2023

39. Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jul. 29, 2024).

Subjects
PHARMACEUTICAL biotechnology industry, INDUSTRY classification, BIOTECHNOLOGY industries, SECURITY holders, DRUGS
Abstract

Can-Fite Biopharma Ltd., a biopharmaceutical company, has filed a Form 6-K with the U.S. Securities and Exchange Commission (SEC). The filing contains information required to be made public in the company's domicile country and is not considered "filed" for liability purposes. The SEC filing is a formal document or financial statement submitted by publicly-traded companies. For more information on the filing, readers can visit the SEC's website. [Extracted from the article]

Published
2024

40. Can-fite Biopharma Ltd. Files SEC Form 424B7, Prospectus [Rule 424(B)(7)]: (Jun. 28, 2024).

Subjects
PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries, INDUSTRY classification
Abstract

Can-Fite Biopharma Ltd., a biopharmaceutical company, has filed a Form 424B7 with the U.S. Securities and Exchange Commission (SEC). The filing includes a prospectus submitted under Rule 424(b)(7). This SEC filing is a formal document or financial statement that publicly-traded companies submit to the SEC. The filing can be accessed on the SEC's website for more information. Can-Fite Biopharma Ltd. is involved in the development of drugs and therapies in the field of healthcare biotechnology. [Extracted from the article]

Published
2024

41. Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Jun. 24, 2024).

Subjects
PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries, INDUSTRY classification, SECURITY holders
Abstract

Can-Fite Biopharma Ltd., a biopharmaceutical company, has filed a Form 6-K with the U.S. Securities and Exchange Commission (SEC). The filing contains information required to be made public in the company's domicile country and is not considered "filed" for liability purposes. The SEC filing is a formal document or financial statement submitted by publicly-traded companies. For more information on the filing, readers can visit the SEC's website. [Extracted from the article]

Published
2024

42. CANF notifies new data on Namodenoso's anti-obesity mechanism of action

Subjects
Can-Fite BioPharma Ltd., Obesity, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new [...]

Published
2023

43. The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Subjects
Can-Fite BioPharma Ltd., Medical research, Medicine, Experimental, Obesity -- Care and treatment, Weight reducing preparations, Pharmaceutical industry, Business, Business, international
Abstract

Robust support for Namodenoson's potential development as an anti-obesity drug, a projected $100 billion market by 2030 PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a [...]

Published
2023

44. Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Psoriasis -- Care and treatment, Pediatrics, Pharmaceutical industry, Business, Business, international
Abstract

* FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson's good safety profile * There is an unmet need for safe, convenient, and effective drugs to [...]

Published
2023

46. Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Subjects
Can-Fite BioPharma Ltd., Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

PETACH TIKVA, Israel: Can-Fite BioPharma Ltd. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule [...]

Published
2023

47. 424B3: Can-Fite BioPharma Ltd

Subjects
United States. Securities and Exchange Commission, Can-Fite BioPharma Ltd., Cybernet Data Systems Inc., Computer services industry, Pharmaceutical industry, Computer services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- Filed Pursuant to Rule 424(b)(3) Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2023) Filed Pursuant to Rule 424(b)(3) 846,818,700 Ordinary [...]

Published
2023

48. Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Subjects
United States. Securities and Exchange Commission, Can-Fite BioPharma Ltd., Pharmaceutical industry, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the [...]

Published
2023

49. Can-Fite participated in Liver Cancer Study & treated with noodenoson

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Oncology, Experimental, Liver cancer -- Care and treatment, Cancer -- Research, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that [...]

Published
2023

50. CAN-FITE, COMPLETE RESPONSE AND 6.9 YEARS OVERALL SURVIVAL IN A PATIENT WITH ADVANCED LIVER CANCER TREATED WITH NAMODENOSON

Subjects
United States. Food and Drug Administration, Can-Fite BioPharma Ltd., Pharmaceutical industry
Abstract

ENPNewswire-November 22, 2023--CAN-FITE, COMPLETE RESPONSE AND 6.9 YEARS OVERALL SURVIVAL IN A PATIENT WITH ADVANCED LIVER CANCER TREATED WITH NAMODENOSON (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 21112023 - Israel - [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results